Skip to main content
Figure 1 | Orphanet Journal of Rare Diseases

Figure 1

From: No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - a pilot study

Figure 1

Innovativeness versus cost matrix for centrally authorised drugs with and without orphan status. X-axis depicts therapeutic innovativeness, while the Y-axis shows average cost per DDD rank. The size of the bubbles describes the variability in use across the countries in the study. Exact locations in the matrix are shown by dots within the bubbles. No statistically significant difference in variation in use was found (P = 0.52).

Back to article page